Results 81 to 90 of about 8,460 (122)

Cytomegalovirus Colitis during Budesonide Therapy for Ulcerative Colitis. [PDF]

Intern Med
Tamazawa K, Aizawa M, Wada J, Ishizaki N, Suzuki K, Otomo K, Takagi T, Togashi K, Ohira H.   +8 more
europepmc   +1 more source

Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years. [PDF]

Pharmaceuticals (Basel), 2023
Imbrizi M, Magro F, Coy CSR.
europepmc   +1 more source

Global Trends in the Research of Ulcerative Colitis Treatments (2021-2025): A Bibliometric Review. [PDF]

Cureus
Zapatier J, Nichols E, Reddy VN, Ganti L.   +3 more
europepmc   +1 more source

Gut microbiota dysbiosis and immune responses: insights from IgA nephropathy and inflammatory bowel disease. [PDF]

Front Immunol
Yi L, Zhang R, Yang Y, Wen X, Wang Y, Zeng F, Xu G.   +6 more
europepmc   +1 more source

From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis. [PDF]

Z Gastroenterol
Schnoy E, Dignass A, Gaskins M, Kucharzik T.   +3 more
europepmc   +1 more source

Real-world effectiveness and safety of carotegrast methyl in patients with ulcerative colitis: a multicenter retrospective cohort study. [PDF]

Intest Res
Koshiba R, Kakimoto K, Inoue T, Sanomura M, Murano M, Ito H, Nakanishi Y, Kawakami K, Mizuta N, Numa K, Kinoshita N, Nakazawa K, Hara A, Hirata Y, Sakiyama N, Arimitsu S, Miyazaki T, Nakamura S, Nishikawa H.   +18 more
europepmc   +1 more source

Long-Term Oral Budesonide Use in Inflammatory Bowel Disease: Effects on Bone Mineral Density and Late-Onset Adverse Events. [PDF]

Diagnostics (Basel)
Eskazan T, Bakkaloglu OK, Durcan E, Akpinar A, Kurt EA, Onal U, Erzin YZ, Hatemi AI, Celik AF.   +8 more
europepmc   +1 more source

Case Report: Successful anti-TNF antibody therapy in steroid-dependent segmental colitis associated with diverticulosis and concomitant ulcerative colitis. [PDF]

Front Immunol
Fousekis F, Siebler J, Rath T, Hartmann A, Neurath MF, Vieth M, Atreya R.   +6 more
europepmc   +1 more source

The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis. [PDF]

Front Gastroenterol (Lausanne)
Paridaens K, Freddi MJ, Travis SPL.
europepmc   +1 more source

Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. [PDF]

BMJ Open
Cristoferi L, D'Amato D, Maino C, Bernasconi D, Dinelli ME, Malandrin SMI, Facciotti F, Viganò C, Pirola L, Festa MM, Gerussi A, Rossi E, Malinverno F, Tettamanti P, Cazzaniga ME, Corso R, Ippolito D, Galimberti S, Invernizzi P, Carbone M.   +19 more
europepmc   +1 more source